Aligos Therapeutics (ALGS) Equity Ratio (2021 - 2025)
Historic Equity Ratio for Aligos Therapeutics (ALGS) over the last 5 years, with Q3 2025 value amounting to 0.65.
- Aligos Therapeutics' Equity Ratio rose 1551.57% to 0.65 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.65, marking a year-over-year increase of 1551.57%. This contributed to the annual value of 0.41 for FY2024, which is 16802.01% down from last year.
- According to the latest figures from Q3 2025, Aligos Therapeutics' Equity Ratio is 0.65, which was up 1551.57% from 0.76 recorded in Q2 2025.
- In the past 5 years, Aligos Therapeutics' Equity Ratio ranged from a high of 0.83 in Q1 2021 and a low of 0.41 during Q4 2024
- In the last 5 years, Aligos Therapeutics' Equity Ratio had a median value of 0.71 in 2022 and averaged 0.64.
- In the last 5 years, Aligos Therapeutics' Equity Ratio plummeted by 16802.01% in 2024 and then surged by 6527.82% in 2025.
- Over the past 5 years, Aligos Therapeutics' Equity Ratio (Quarter) stood at 0.78 in 2021, then decreased by 9.76% to 0.71 in 2022, then dropped by 14.2% to 0.61 in 2023, then plummeted by 168.02% to 0.41 in 2024, then surged by 258.33% to 0.65 in 2025.
- Its Equity Ratio was 0.65 in Q3 2025, compared to 0.76 in Q2 2025 and 0.77 in Q1 2025.